RAS結合ペプチドを用いて選択的にmTORC2を抑制するためにRAS- mSIN1の相互作用を活用する:乳癌の転移への影響
PubMedで要約を見る
まとめ
この要約は機械生成です。研究者は,がん転移の重要な要因であるmTORC2を選択的に抑制する新しいペプチド (S-016-1034) を開発した. この標的型アプローチは,Ras-mSIN1の相互作用を妨害することで,新しいがん治療法の開発に希望を示しています.
科学分野
- 腫瘍学
- 分子生物学
- 薬物の発見
背景
- ラパミシン複合体2 (mTORC2) のメカニズム的標的は,がんの進行と転移において重要な役割を果たします.
- mTORC1に影響を及ぼさず,mTORC2の選択的抑制は,がん治療における重要な満たされていない需要である.
研究 の 目的
- RAS- mSIN1の相互作用を標的とした選択的なmTORC2阻害のための戦略を開発する.
- mSIN1のRAS結合領域から派生した新しいペプチドの有効性を調査する.
主な方法
- mSIN1のRAS結合領域を標的にする11-マーペプチド (S-016-1034) の開発.
- ペプチド-ラスの結合を確認するために,細胞フリーバイオレイヤー-インターフェロメトリー (BLI) を行う.
- コンフォカル顕微鏡検査とフローサイトメトリーは,細胞膜の浸透を評価する.
- Ras-mSin1相互作用の障害を評価するために,細胞ベースのアッセイ (免疫プレシピテーション,in-situ近接結合)
- mTORC2の特異性を確認するために,トランスクリプトミクス,細胞ベースの測定,および体内モデル (C. elegans,4T1/Balb/cマウス).
主要な成果
- ペプチドS-016-1034は Rasに直接結合することが示されました.
- ペプチドは非エンドソーマル経路で細胞膜に突入しました.
- Ras- mSin1の相互作用を阻害することで,mTORC1よりもmTORC2を選択的に抑制した.
- mTORC2抑制の特異性は,乳がんマウスモデルを含む様々なモデルで確認されました.
結論
- Ras結合ペプチドS-016-1034は選択的にmTORC2を阻害する.
- このペプチドのさらなる最適化により,がん細胞の侵入と転移を阻止する有望な治療戦略が開発される可能性があります.
関連する概念動画
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

